P19INK4d mRNA and protein expression as new prognostic factors in ovarian cancer patients

Cancer Biology and Therapy

Volumn 14, Issue 10, 2013, Pages 973-981

  Felisiak Golabek, Anna ^a   Dansonka Mieszkowska, Agnieszka ^a   Rzepecka, Iwona K ^a   Szafron, Lukasz ^a   Kwiatkowska, Ewa ^a   Konopka, Bozena ^a   Podgorska, Agnieszka ^a   Rembiszewska, Alina ^a   Kupryjanczyk, Jolanta ^a  

^a INSTITUTE OF ONCOLOGY   (Poland)

Author keywords

CDKN2D; Chemotherapy; Immunohistochemistry; Ovarian cancer; p19 INK4d; Prognostic factor; Real time qPCR; TP53

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE INHIBITOR 2D; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; PACLITAXEL; PROTEIN P53; CDKN2D PROTEIN, HUMAN; MESSENGER RNA; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PREDICTIVE VALUE; PROTEIN EXPRESSION; CDKN2D; CHEMOTHERAPY; GENE EXPRESSION; GENETIC POLYMORPHISM; GENETICS; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEOPLASM; OVARY CANCER; OVARY TUMOR; P19INK4D; PATHOLOGY; PROGNOSIS; PROGNOSTIC FACTOR; REAL-TIME QPCR; TP53; YOUNG ADULT;

CDKN2D; CHEMOTHERAPY; IMMUNOHISTOCHEMISTRY; OVARIAN CANCER; P19INK4D; PROGNOSTIC FACTOR; REAL-TIME QPCR; TP53;

ADULT; AGED; CYCLIN-DEPENDENT KINASE INHIBITOR P19; FEMALE; GENE EXPRESSION; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; POLYMORPHISM, GENETIC; PROGNOSIS; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84885207355     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.25966     Document Type: Article

References (45)

1. McGuire W P, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group). Semin Oncol 1996; 23(Suppl 12):40-7; PMID:8941409 (Pubitemid 26391379)
2. Trimble EL, Wright J, Christian MC. Treatment of platinum-resistant ovarian cancer. Expert Opin Pharmacother 2001; 2:1299-306; PMID:11584998; http://dx.doi.org/10.1517/14656566.2.8.1299 (Pubitemid 32750369)
3. Stuart GCE. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003; 90:S8-15; PMID:13129490; http://dx.doi.org/10.1016/S0090-8258(03)00472-4
4. Kupryjanczyk J, Kraszewska E, Ziółkowska-Seta I, Madry R, Timorek A, Markowska J, Stelmachow J, Bidzinski M; Polish Ovarian Cancer Study Group (POCSG). TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: a non-randomized retrospective study. BMC Cancer 2008; 8:27; PMID:18230133; http://dx.doi. org/10.1186/1471-2407-8-27
5. Roussel M F. The INK4 family of cell cycle inhibitors in cancer. Oncogene 1999; 18:5311-7; PMID:10498883; http://dx.doi.org/10.1038/sj.onc.1202998 (Pubitemid 29462366)
6. INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta 1998; 1378:F115-77; PMID:9823374 (Pubitemid 28530512)
7. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 2002; 1602:73-87; PMID:11960696 (Pubitemid 34311901)
8. Hirai H, Roussel M F, Kato J-Y, Ashmun RA, Sherr CJ. Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol Cell Biol 1995; 15:2672-81; PMID:7739547
9. INK4d. FEBS Lett 1997; 401:127-32; PMID:9013872; http://dx.doi. org/10.1016/S0014- 5793(96)01465-2 (Pubitemid 27056101)
10. Marazita MC, Ogara MF, Sonzogni SV, Martí M, Dusetti NJ, Pignataro O P, Cánepa ET. CDK2 and PKA mediated-sequential phosphorylation is critical for p19INK4d function in the DNA damage response. PLoS One 2012; 7:e35638; PMID:22558186; http://dx.doi.org/10.1371/journal.pone.0035638
11. INK4d, a p16-related inhibitor specific to CDK6 and CDK4. Mol Biol Cell 1996; 7:57-70; PMID:8741839
12. Han J, Ito Y, Yeo JY, Sucov HM, Maas R, Chai Y. Cranical neural crest-derived mesenchymal proliferation is regulated by Msx1-mediated p19INK4d expression during odontogenesis. Dev Bio 2003; l61:183-96; http://dx.doi.org/10. 1016/S0012-1606(03)00300-2. (Pubitemid 36993826)
13. INK4d determines its periodic expression during the cell cycle. Oncogene 2000; 19:2870-6; PMID:10851091; http://dx.doi. org/10.1038/sj.onc.1203579 (Pubitemid 30386424)
14. INK4d in human testicular germ-cell tumours contrasts with high expression during normal spermatogenesis. Oncogene 2000; 19:4146-50; PMID:10962575; http://dx.doi. org/10.1038/sj.onc.1203769
15. Bartkova J, Rajpert-De Meyts E, Skakkebaek NE, Lukas J, Bartek J. Deregulation of the G1/S-phase control in human testicular germ cell tumours. APMIS 2003; 111:252-65, discussion 265-6; PMID:12760379; http://dx.doi.org/10. 1034/j.1600-0463.2003.1110129.x
16. Zhang W, Zeng Z, Zhou Y, Xiong W, Fan S, Xiao L, Huang D, Li Z, Li D, Wu M, et al. Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis. Acta Biochim Biophys Sin (Shanghai) 2009; 41:414-28; PMID:19430707; http://dx.doi.org/10.1093/abbs/gmp025
17. Kmet LM, Cook LS, Magliocco AM. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Cancer 2003; 97:389-404; PMID:12518363; http://dx.doi.org/10.1002/cncr. 11064 (Pubitemid 36133806)
18. Smith-Sørensen B, Kaern J, Holm R, Dørum A, Tropé C, Børresen-Dale A-L. Therapy effect of either paclitaxel or cyclophosphamide combination treatment in patients with epithelial ovarian cancer and relation to TP53 gene status. Br J Cancer 1998; 78:375-81; PMID:9703286; http://dx.doi.org/10.1038/bjc.1998.502 (Pubitemid 28336426)
19. Ueno Y, Enomoto T, Otsuki Y, Sugita N, Nakashima R, Yoshino K, Kuragaki C, Ueda Y, Aki T, Ikegami H, et al. Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of pacli-taxel and carboplatin. Cancer Lett 2006; 241:289-300; PMID:16459017; http://dx.doi.org/10.1016/j. canlet.2005.10.035 (Pubitemid 44163043)
20. Herod JJO, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res 1996; 56:2178-84; PMID:8616869 (Pubitemid 26119922)
21. Bellamy CO. p53 and apoptosis. Br Med Bull 1997; 53:522-38; PMID:9374035; http://dx.doi. org/10.1093/oxfordjournals.bmb.a011628 (Pubitemid 27397308)
22. Jones NA, Turner J, McIlwrath AJ, Brown R, Dive C. Cisplatin-and paclitaxel-induced apoptosis of ovarian carcinoma cells and the relationship between bax and bak up-regulation and the functional status of p53. Mol Pharmacol 1998; 53:819-26; PMID:9584207 (Pubitemid 28244068)
23. Shimada M, Kigawa J, Kanamori Y, Itamochi H, Takahashi M, Kamazawa S, Sato S, Terakawa N. Mechanism of the combination effect of wild-type TP53 gene transfection and cisplatin treatment for ovarian cancer xenografts. Eur J Cancer 2000; 36:1869-75; PMID:10974636; http://dx.doi.org/10.1016/S0959-8049(00)00161- 1 (Pubitemid 30639508)
24. Kupryjanczyk J, Szymanska T, Madry R, Timorek A, Stelmachów J, Karpinska G, Rembiszewska A, Ziółkowska I, Kraszewska E, Debniak J, et al. Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen. Br J Cancer 2003; 88:848-54; PMID:12644821; http://dx.doi. org/10.1038/sj.bjc.6600789 (Pubitemid 36520871)
25. Kupryjanczyk J, Madry R, Plisiecka-Hałasa J, Bar J, Kraszewska E, Ziółkowska I, Timorek A, Stelmachów J, Emerich J, Jedryka M, et al. TP53 status determines clinical significance of ERBB2 expression in ovarian cancer. Br J Cancer 2004; 91:1916-23; PMID:15545967; http://dx.doi.org/10.1038/sj.bjc.6602238 (Pubitemid 40065521)
26. Felisiak-Golabek A, Rembiszewska A, Rzepecka IK, Szafron L, Madry R, Murawska M, Napiorkowski T, Sobiczewski P, Osuch B, Kupryjanczyk J; Polish Ovarian Cancer Study Group (POCSG). Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients. J Ovarian Res 2011; 4:20; PMID:22075440; http://dx.doi.org/10.1186/1757-2215-4-20
27. Thullberg M, Welcker M, Bartkova J, Kjerulff AA, Lukas J, Högberg J, Bartek J. Monoclonal antibody probes for p21WAF1/CIP1 and the INK4 family of cyclin-dependent kinase inhibitors. Hybridoma 2000; 19:63-72; PMID:10768842; http://dx.doi. org/10.1089/027245700315806 (Pubitemid 30184972)
28. Ceruti JM, Scassa ME, Fló JM, Varone CL, Cánepa E T. Induction of p19INK4d in response to ultraviolet light improves DNA repair and confers resistance to apoptosis in neuroblastoma cells. Oncogene 2005; 24:4065-80; PMID:15750620; http://dx.doi. org/10.1038/sj.onc.1208570 (Pubitemid 40897053)
29. Kupryjanczyk J. Why TP53 status does not associate with clinical endpoints in ovarian cancer: facts and hypotheses. Gynecol Oncol 2006; 100:5-7; PMID:16169062; http://dx.doi.org/10.1016/j. ygyno.2005.08.003 (Pubitemid 41815041)
30. Ceruti JM, Scassa ME, Marazita MC, Carcagno AC, Sirkin P F, Cánepa ET. Transcriptional upregulation of p19INK4d upon diverse genotoxic stress is critical for optimal DNA damage response. Int J Biochem Cell Biol 2009; 41:1344-53; PMID:19130897; http://dx.doi.org/10.1016/j.biocel.2008.12.005
31. Scassa ME, Marazita MC, Ceruti JM, Carcagno AL, Sirkin P F, González-Cid M, Pignataro O P, Cánepa E T. Cell cycle inhibitor, p19INK4d, promotes cell survival and decreases chromosomal aberrations after genotoxic insult due to enhanced DNA repair. DNA Repair (Amst) 2007; 6:626-38; PMID:17218167; http://dx.doi.org/10.1016/j.dnarep.2006.12.003 (Pubitemid 46518331)
32. INK4a tumor suppressor versus other INK4 family members during mouse development and aging. Oncogene 1997; 15:203-11; PMID:9244355; http://dx.doi.org/10.1038/sj.onc.1201178 (Pubitemid 27344559)
33. Zindy F, van Deursen J, Grosveld G, Sherr CJ, Roussel M F. INK4d-deficient mice are fertile despite testicular atrophy. Mol Cell Biol 2000; 20:372-8; PMID:10594039; http://dx.doi.org/10.1128/MCB.20.1.372-378.2000 (Pubitemid 30002578)
34. INK4D cyclin dependent kinase inhibitor gene is altered in osteosarcoma. Oncogene 1997; 15:231-5; PMID:9244358; http://dx.doi. org/10.1038/sj.onc.1201185 (Pubitemid 27344562)
35. Gemma A, Takenoshita S, Hagiwara K, Okamoto A, Spillare EA, McMemamin MG, Hussain S P, Forrester K, Zariwala M, Xiong Y, et al. Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines. Int J Cancer 1996; 68:605-11; PMID:8938142; http://dx.doi.org/10.1002/(SICI)1097-0215(19961127)68:53.0.CO;2-2
36. Zariwala M, Xiong Y. Lack of mutation in the cyclin-dependent kinase inhibitor, p19INK4d, in tumor-derived cell lines and primary tumors. Oncogene 1996; 13:2033-8; PMID:8934552 (Pubitemid 26397465)
37. Shiohara M, Spirin K, Said J W, Gombart A F, Nakamaki T, Takeuchi S, Hatta Y, Morosetti R, Tasaka T, Seriu T, et al. Alterations of the cyclin-dependent kinase inhibitor p19 (INK4D) is rare in hematopoietic malignancies. Leukemia 1996; 10:1897-900; PMID:8946928
38. Park DJ, Wilczynski S P, Pham EY, Miller CW, Koeffler H P. Molecular analysis of the INK4 family of genes in prostate carcinomas. J Urol 1997; 157:1995-9; PMID:9112579; http://dx.doi.org/10.1016/S0022-5347(01)64917-6 (Pubitemid 27171827)
39. Creasman WJ. Announcement, FIGO stages 1988, revisions. Gynecol Oncol 1989; 35:125-7
40. Tavassoli FA, Devilee P. Edited: pathology and genetics of tumours of the breast and female genital organs World Health Organisation classification of tumours. IARC Press Lyon 2003.
41. Barber HR, Sommers SC, Synder R, Kwon TH. Histologic and nuclear grading and stromal reactions as indices for prognosis in ovarian cancer. Am J Obstet Gynecol 1975; 121:795-807; PMID:1092171
42. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47:207-14; PMID:7459811; http://dx.doi. org/10.1002/1097-0142(19810101)47:13.0.CO;2-6 (Pubitemid 11167383)
43. Christian MC, Trimble EL. Salvage chemotherapy for epithelial ovarian carcinoma. Gynecol Oncol 1994; 55:S143-50; PMID:7835799; http://dx.doi. org/10.1006/gyno.1994.1354
44. Dansonka-Mieszkowska A, Ludwig AH, Kraszewska E, Kupryjanczyk J. Geographical variations in TP53 mutational spectrum in ovarian carcinomas. Ann Hum Genet 2006; 70:594-604; PMID:16907706; http://dx.doi.org/10.1111/j.1469- 1809.2006.00257.x (Pubitemid 44173371)
45. Kolasa IK, Rembiszewska A, Janiec-Jankowska A, Dansonka-Mieszkowska A, Lewandowska AM, Konopka B, Kupryjanczyk J. PTEN mutation, expression and LOH at its locus in ovarian carcinomas. Relation to TP53, K-RAS and BRCA1 mutations. Gynecol Oncol 2006; 103:692-7; PMID:16793127; http://dx.doi.org/10.1016/j.ygyno. 2006.05.007 (Pubitemid 44602189)